Medical News

MS in Children –⁠ An Overlooked Sister of Adult Diseases?

6. 6. 2022 Source: Multiple Sclerosis

Multiple sclerosis is not just an adult disease. How common is it in children and how have current therapeutic possibilities advanced for this population both in our country and around the world?

Safety and Efficacy of Bimekizumab Self-Administration in Psoriasis Patients

Patient adherence to regular administration of biologic therapy is crucial for its effectiveness. The studies presented below evaluated self-administration of the humanized monoclonal antibody…

3. 6. 2022 Source: Psoriasis

Efficacy and Safety of Teriflunomide in the Treatment of Multiple Sclerosis in Children –⁠ Results of the TERIKIDS Study

Therapeutic options for multiple sclerosis in the pediatric population are limited. However, in June 2021, teriflunomide was approved for the treatment of relapsing-remitting multiple sclerosis…

1. 6. 2022 Source: Multiple Sclerosis

Cost-Effectiveness of Eletriptan in Acute Migraine Treatment

Even in a market dominated by generics, eletriptan 40 mg is among the most clinically effective and cost-efficient triptans for the acute treatment of migraine attacks. This was demonstrated by a…

1. 6. 2022 Source: Treatment of Severe Migraine

Doc. Petr Dulíček: Physical activity in hemophiliacs? Today it is a reality -⁠ just don't be afraid!

Thanks to modern treatment, the lives of hemophiliacs are becoming more active. Patients today can engage in most sports activities. On the contrary, avoiding physical activity carries the risk of…

30. 5. 2022 Source: Hemophilia with Movement

Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population

Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does...

30. 5. 2022 Source: Hemophilia with Movement

Tofacitinib Helps Restore Intestinal Epithelial Barrier

The Janus kinase inhibitor (JAKi) tofacitinib was relatively recently approved for the treatment of ulcerative colitis, but its effect on the intestinal epithelium remains a subject of research. The…

30. 5. 2022 Source: Intestinal Inflammations

Safety and Efficacy of Long-term Tofacitinib Therapy in Patients with Active Psoriatic Arthritis –⁠ Interim Results of the OPAL Balance Study

Tofacitinib is a potent selective inhibitor of the Janus kinase (JAK) family indicated for the treatment of active psoriatic arthritis in adult patients. The efficacy and safety of tofacitinib in…

30. 5. 2022 Source: Arthritis

Cardiovascular Safety of Tofacitinib in Real-World Clinical Practice –⁠ Results of the STAR-RA Study

Recent results from the ORAL Surveillance clinical trial have raised concerns about the cardiovascular adverse effects of tofacitinib in patients with rheumatoid arthritis. A comprehensive analysis…

29. 5. 2022 Source: Arthritis

Maintenance of Remission with Tofacitinib in Patients with UC –⁠ Results of the OCTAVE Open Study

Tofacitinib is indicated for the treatment of ulcerative colitis (UC) in cases where conventional treatment or monoclonal antibodies do not yield sufficient results. Key benefits of this medication…

28. 5. 2022 Source: Intestinal Inflammations

1 … 72 73 74 75 76 … 164

Back Filter by speciality

Remove filters